QRxPharma has reported a contractual agreement with Patheon to manufacture clinical supplies of its controlled release Dual-Opioid formulation – MoxDuoCR. MoxDuoCR is designed to provide 12 hours of pain relief in patients suffering from moderate-to-severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).
Reportedly, the new formulation includes tamper resistant features and is designed to provide 12 hours of pain relief. The company’s MoxDuo product portfolio includes immediate release, controlled release and intravenous formulations to address pain management in hospitals and at home.
John Holaday, managing director and CEO at QrxPharma, said: “The Patheon relationship represents a major step forward for QRxPharma that rounds out our platform of MoxDuo products. Our goal is to provide physicians and patients with a variety of complementary Dual Opioids for managing moderate to severe pain. MoxDuoCR is expected to deliver clinical benefits similar to those clinically demonstrated with MoxDuoIR (immediate release formulation) – fewer side effects and superior pain relief.
“We are targeting a twice daily dosage with MoxDuoCR, and we anticipate our initial phase 1 studies will begin this year to evaluate the pharmacokinetic profile of this patented formulation. QRxPharma’s most advanced product for treating acute pain, MoxDuoIR, is now in phase 3 trials and scheduled for New Drug Application (NDA) filing with the FDA in 2010. QRxPharma’s formulation of MoxDuoCR is anticipated to complete clinical trials in 2012.”
Wes Wheeler, CEO of Patheon, said: “We are pleased to announce this manufacturing agreement with QRxPharma for MoxDuoCR; we are making significant progress with clinical formulations of this unique Dual-Opioid product.”